In order to exclude that GPIIb-IIIa from additional (non-platelet, non-melanoma cell) sources contributes to melanoma cell-aggregate formation and retention in vivo, we performed an additional set of experiments in which GPIIb-/- mice were treated with GPIIb-/- or WT platelets prior to administration of DCF-labeled B16-D5. The gene discussed is ITGA2B; the disease is melanoma.